Key result
De novo HFrEF in Graves' disease linked to ~417% higher all-cause mortality risk.
Why the study?
Graves' disease can aggravate pre-existing cardiac disease and cause de novo heart failure, but large-scale studies are lacking.
What are the incidence, risk factors, and outcomes of de novo heart failure in patients with Graves' disease?
Cohort (n=1,371)
What are the incidence, risk factors, and outcomes of de novo heart failure in patients with Graves' disease?
De novo heart failure occurs in 5.4% of patients with Graves' disease and is associated with significantly increased risks of cardiovascular hospitalizations and, particularly for HFrEF, all-cause mortality and ventricular arrhythmias.
May warrant HF surveillance in Graves' disease; observational data leaves open whether interventions improve outcomes.
OBJECTIVE: Graves' disease (GD) can both aggravate pre-existing cardiac disease and cause de novo heart failure (HF), but large-scale studies are lacking. We aimed to investigate the incidence, risk factors and outcomes of incident GD-related HF. METHODS: Patients with GD (2009-2019) were retrospectively included. HF with reduced ejection fraction (HFrEF) was defined by left ventricular ejection fraction <50% and Framingham criteria, while HF with preserved ejection fraction (HFpEF) was defined according to the HFA-PEFF criteria. HF due to ischaemia, valve disorder or other structural heart disease was excluded. Proportional hazards regression was used to analyse risk factors and outcomes. RESULTS: Of 1371 patients with GD, HF occurred in 74 (5.4%) patients (31 (2.3%) HFrEF; 43 (3.1%) HFpEF). In HFrEF, atrial fibrillation (AF) (HR 10.5 (3.0-37.3), p<0.001) and thyrotropin receptor antibody (TRAb) level (HR 1.05 (1.01-1.09) per unit, p=0.007) were independent risk factors. In HFpEF, the independent risk factors were chronic obstructive pulmonary disease (HR 7.2 (3.5-14.6), p<0.001), older age (HR 1.5 (1.2-2.0) per 10 years, p=0.001), overt hyperthyroidism (HR 6.4 (1.5-27.1), p=0.01), higher body mass index (BMI) (HR 1.07 (1.03-1.10) per unit, p=0.001) and hypertension (HR 3.1 (1.3-7.2), p=0.008). The risk of cardiovascular hospitalisations was higher in both HFrEF (HR 10.3 (5.5-19.4), p<0.001) and HFpEF (HR 6.7 (3.7-12.2), p<0.001). However, only HFrEF was associated with an increased risk of all-cause mortality (HR 5.17 (1.3-19.9), p=0.02) and ventricular tachycardia/fibrillation (HR 64.3 (15.9-259.7), p<0.001). CONCLUSION: De novo HF occurs in 5.4% of patients with GD and is associated with increased risk of cardiovascular hospitalisations and mortality. Risk factors include AF, higher TRAb, higher BMI and overt hyperthyroidism.
No takes yet. Share an insight, caveat, or question.
Naser et al. (2021) conducted a cohort in Graves' disease (n=1,371). Graves' disease was evaluated on Incidence of de novo heart failure. De novo heart failure occurred in 5.4% of patients with Graves' disease, with HFrEF significantly increasing the risk of all-cause mortality (HR 5.17; 95% CI 1.3-19.9; p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: